These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 15479081

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Analysis of HIV wild-type and mutant structures via in silico docking against diverse ligand libraries.
    Chang MW, Lindstrom W, Olson AJ, Belew RK.
    J Chem Inf Model; 2007; 47(3):1258-62. PubMed ID: 17447753
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
    Santos-Filho OA, Hopfinger AJ.
    J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Conformational flexibility in the flap domains of ligand-free HIV protease.
    Heaslet H, Rosenfeld R, Giffin M, Lin YC, Tam K, Torbett BE, Elder JH, McRee DE, Stout CD.
    Acta Crystallogr D Biol Crystallogr; 2007 Aug; 63(Pt 8):866-75. PubMed ID: 17642513
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Improving binding mode predictions by docking into protein-specifically adapted potential fields.
    Radestock S, Böhm M, Gohlke H.
    J Med Chem; 2005 Aug 25; 48(17):5466-79. PubMed ID: 16107145
    [Abstract] [Full Text] [Related]

  • 33. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
    Thaisrivongs S, Romero DL, Tommasi RA, Janakiraman MN, Strohbach JW, Turner SR, Biles C, Morge RR, Johnson PD, Aristoff PA, Tomich PK, Lynn JC, Horng MM, Chong KT, Hinshaw RR, Howe WJ, Finzel BC, Watenpaugh KD.
    J Med Chem; 1996 Nov 08; 39(23):4630-42. PubMed ID: 8917652
    [Abstract] [Full Text] [Related]

  • 34. Enhancing specificity and sensitivity of pharmacophore-based virtual screening by incorporating chemical and shape features--a case study of HIV protease inhibitors.
    Pandit D, So SS, Sun H.
    J Chem Inf Model; 2006 Nov 08; 46(3):1236-44. PubMed ID: 16711743
    [Abstract] [Full Text] [Related]

  • 35. Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction.
    Pillai B, Kannan KK, Bhat SV, Hosur MV.
    Acta Crystallogr D Biol Crystallogr; 2004 Mar 08; 60(Pt 3):594-6. PubMed ID: 14993705
    [Abstract] [Full Text] [Related]

  • 36. Restrained molecular dynamics simulations of HIV-1 protease: the first step in validating a new target for drug design.
    Perryman AL, Lin JH, McCammon JA.
    Biopolymers; 2006 Jun 15; 82(3):272-84. PubMed ID: 16508951
    [Abstract] [Full Text] [Related]

  • 37. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
    Sperka T, Pitlik J, Bagossi P, Tözsér J.
    Bioorg Med Chem Lett; 2005 Jun 15; 15(12):3086-90. PubMed ID: 15893929
    [Abstract] [Full Text] [Related]

  • 38. Structural parameterization of the binding enthalpy of small ligands.
    Luque I, Freire E.
    Proteins; 2002 Nov 01; 49(2):181-90. PubMed ID: 12210999
    [Abstract] [Full Text] [Related]

  • 39. HIV-1 protease folding and the design of drugs which do not create resistance.
    Broglia R, Levy Y, Tiana G.
    Curr Opin Struct Biol; 2008 Feb 01; 18(1):60-6. PubMed ID: 18160276
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.